Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan P Knox

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
JAMA|September 20, 2022
Risks to the 340B Drug Pricing Program-ReplyRyan P Knox, Ameet Sarpatwari
Health Affairs Scholar|August 6, 2025
Legal challenges to the 340B drug pricing program: administration, regulation, and reformRyan P Knox, Ameet Sarpatwari
JAMA|May 18, 2026
The 340B Drug Pricing Program at a CrossroadsRyan P Knox, Ameet Sarpatwari
Journal of Law and the Biosciences|September 16, 2024
Biosimilar approval pathways: comparing the roles of five medicines regulatorsRyan P Knox, Vineet Desai, Ameet Sarpatwari
Annals of Surgery|July 31, 2025
From Clinics to Courtrooms: Strategies to Protect Surgeons and Preserve Access to Gender-Affirming SurgeryCoral Katave, Ryan P Knox, Kavitha Ranganathan
JAMA|April 15, 2022
Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug AvailabilityRyan P Knox, Aaron S Kesselheim, Ameet Sarpatwari
JAMA Health Forum|October 11, 2022
Independent Pharmacies Gain Unanimous Victory in Recent US Supreme Court CaseRyan P Knox, Deepen Gagneja, Katherine L Kraschel
JAMA Health Forum|November 22, 2023
Outcomes of the 340B Drug Pricing Program: A Scoping ReviewRyan P Knox, Junyi Wang, William B Feldman, et al.
Plos Medicine|November 16, 2023
Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986-2019Anders Olsen, Reed F Beall, Ryan P Knox, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
JAMA|September 20, 2022
Risks to the 340B Drug Pricing Program-ReplyRyan P Knox, Ameet Sarpatwari
Health Affairs Scholar|August 6, 2025
Legal challenges to the 340B drug pricing program: administration, regulation, and reformRyan P Knox, Ameet Sarpatwari
JAMA|May 18, 2026
The 340B Drug Pricing Program at a CrossroadsRyan P Knox, Ameet Sarpatwari
Journal of Law and the Biosciences|September 16, 2024
Biosimilar approval pathways: comparing the roles of five medicines regulatorsRyan P Knox, Vineet Desai, Ameet Sarpatwari
Annals of Surgery|July 31, 2025
From Clinics to Courtrooms: Strategies to Protect Surgeons and Preserve Access to Gender-Affirming SurgeryCoral Katave, Ryan P Knox, Kavitha Ranganathan
JAMA|April 15, 2022
Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug AvailabilityRyan P Knox, Aaron S Kesselheim, Ameet Sarpatwari
JAMA Health Forum|October 11, 2022
Independent Pharmacies Gain Unanimous Victory in Recent US Supreme Court CaseRyan P Knox, Deepen Gagneja, Katherine L Kraschel
JAMA Health Forum|November 22, 2023
Outcomes of the 340B Drug Pricing Program: A Scoping ReviewRyan P Knox, Junyi Wang, William B Feldman, et al.
Plos Medicine|November 16, 2023
Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986-2019Anders Olsen, Reed F Beall, Ryan P Knox, et al.
Pageof 1